Fibromiyomatöz Stromalı Renal Hücreli Karsinom için İmmünohistokimyasal Tanı Algoritması
PDF

Editöre Mektup

Fibromiyomatöz Stromalı Renal Hücreli Karsinom için İmmünohistokimyasal Tanı Algoritması

Bezmialem Science 2025;13(4):373-375 DOI: 10.14235/bas.galenos.2025.82956
,
PDF
İzin

Kaynakça

1

Shah RB. Renal cell carcinoma with fibromyomatous stroma-the whole story. Adv Anat Pathol. 2022;29:168-77.

2

Shah RB, Stohr BA, Tu ZJ, Gao Y, Przybycin CG, Nguyen J, et al. “Renal cell carcinoma with leiomyomatous stroma” harbor somatic mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity. Am J Surg Pathol. 2020;44:571-81.

3

Moch HH, Humphery PA, Ulbright TM, Reuter VE. WHO classification of tumours of the urinary system and male genital organs. Lyon, France: International Agency for Research on Cancer; 2016.p.164-5.

4

Li H, Argani P, Halper-Stromberg E, Lotan TL, Merino MJ, Reuter VE, et al. Positive GPNMB immunostaining differentiates renal cell carcinoma with fibromyomatous stroma associated with TSC1/2/MTOR alterations from others. Am J Surg Pathol. 2023;47:1267-73.

5

Akgul M, Sangoi AR, Williamson SR. GATA3 in renal neoplasms: increased utility and potential pitfalls. Int J Surg Pathol. 2024;32: 365-7.